Time: 2015.8.17 (Monday) 10:00
Location: Conference room at the first floo of catalysis building
Lecturer: Prof. Wenhui Hu
Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Science
Abstract:
To be a drug candidate, a small molecule must meet all of the requirements of pharmacodynamics and pharmacokinetics properties. We will introduce one of our successful case studies of drug discovery in terms of diabetes. A lead compound as DPP-IV inhibitors was rapidly generated based on the scaffold hopping strategy. The lead optimization was then initiated with a structure and activity studies, followed by a structure and stability relationship along with a structure and absorption relationship studies. A desired drug candidate with excellent efficacy, acceptable PK profiles was finally obtained to support drug development.
Introduction：
Dr. Hu obtained his Ph.D. in Medicinal Chemistry from the Institute of Materia Medica, Chinese Academy of Medical Sciences in 2002. After that, he did the post-doctoral research at the Center for drug discovery and chemical biology, Northwestern University Medical School in the US. He is the Principal Investigator of Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences where he is running multiple drug discovery projects, including anti-diabetic drug discovery, anti-alzheimer’s disease (anti-neuroinflammatory inhibitors) and anti-influenza A drug discovery (M2 inhibitors). He is the owner of several drug candidates and more than 20 publications in high level journals along with 10 PCT patents.
Contacts：Group202 Boshun Wan(9260）